Organofluorine inhibitors of amyloid fibrillogenesis

Biochemistry

Volumn 45, Issue 16, 2006, Pages 5377-5383

  Török, Marianna ^a,b   Abid, Mohammed ^b,c   Mhadgut, Shilpa C ^b,c   Török, Béla ^a,b,c  

^a UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^b MICHIGAN TECHNOLOGICAL UNIVERSITY   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLIC ACIDS; ESTERS; FLUORINE; PROTEINS; STOICHIOMETRY; SYNTHESIS (CHEMICAL);

ACIDIC HYDROXYL GROUP; FIBRILLOGENESIS; ORGANOFLUORINES; PEPTIDE-INHIBITOR INTERACTIONS;

BIOCHEMISTRY;

AMYLOID; AMYLOID BETA PROTEIN[1-40]; CURCUMIN; FERULIC ACID; FURAN DERIVATIVE; INDOLE DERIVATIVE; NAPHTHOQUINONE; ORGANOFLUORINE DERIVATIVE; RIFAMPICIN;

AMYLOIDOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; PRIORITY JOURNAL; PROTEIN ASSEMBLY; STOICHIOMETRY; STRUCTURE ACTIVITY RELATION;

AMYLOID BETA-PROTEIN; DRUG DESIGN; FLUORINE COMPOUNDS; MICROSCOPY, ELECTRON, TRANSMISSION; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33645988190     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi0601104     Document Type: Article

References (53)

1. Lansbury, P. T. (1996) A Reductionist View of Alzheimer's Disease, Acc. Chem. Res. 29, 317-321.
2. Baumeister, R., and Eimer, S. (1998) Amyloid aggregates, presenilins, and Alzheimer's disease, Angew. Chem., Int. Ed. 37, 2978-2982.
3. Wetzel, R., Ed. (1999) Amyloid, Prions, and Other Protein Aggregates, in Methods in Enzymology, Vol. 309, Academic Press, New York.
4. Dobson, C. M. (2003) Protein folding and misfolding, Nature 426, 884-890.
5. Selkoe, D. J. (2003) Folding proteins in fatal ways, Nature 426, 900-904.
6. Golde, T. E. (2003) Alzheimer disease therapy: can the amyloid cascade be halted?, J. Clin. Invest. 111, 11-18.
7. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., and Glabe, C. G. (2003) Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis, Science 300, 486-489.
8. Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., and Klein, W. A. (2003) Proc. Natl. Acad. Sci. U.S.A. 100, 10417-10422.
9. Cohen, F. E., and Kelly, J. W. (2003) Therapeutic approaches to protein-misfolding diseases, Nature 426, 905-909.
10. Wolfe, M. S. (2002) Therapeutic strategies for Alzheimer's disease, Nat. Rev. Drug Discovery 1, 859-866.
11. Murphy, R. M. (2002) Peptide aggregation in neurodegenerative disease, Annu. Rev. Biomed. Eng. 4, 155-174.
12. Petkova, A. T., Ishii, Y., Balbach, J. J., Antzutkin, O. N., Leapman, R. D., Delaglio, F., and Tycko, R. (2002) A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid-state NMR, Proc. Natl. Acad. Sci. U.S.A. 99, 16742-16747.
13. Török, M., Milton, S., Kayed, R., Wu, P., McIntire, T., Glabe, C. G., and Langen, R. (2002) Structural and Dynamic Features of Alzheimer's Aβ Peptide in Amyloid Fibrils Studied by Site-Directed Spin Labeling, J. Biol. Chem. 277, 40810-40815.
14. Thompson, L. K. (2003) Unraveling the secrets of Alzheimer's β-amyloid fibrils, Proc. Natl. Acad. Sci. U.S.A. 100, 383-385.
15. Makin, O. S., Atkins, E., Sikorski, P., Johsnsson, J., and Serpell, L. C. (2005) Molecular basis for amyloid fibril formation and stability, Proc. Natl. Acad. Sci. U.S.A. 102, 315-320.
16. Pastor, M. T., Esteras-Chopo, A., and de la Paz, M. L. (2005) Design of model systems for amyloid formation: lessons for prediction and inhibition, Curr. Opin. Struct. Biol. 15, 57-63.
17. Chalifour, R. J., McLaughlin, R. W., Lavoie, L., Morisette, C., Tremblay, N., Boule, M., Sarazin, P., Stea, D., and Tremblay, P. (2003) Stereoselective Interactions of Peptide Inhibitors with the β-Amyloid Peptide, J. Biol. Chem. 278, 34874-34881.
18. Gordon, D. J., Sciarretta, K. L., and Meredith, S. C. (2001) Inhibition of beta-amyloid(40) fibrillogenesis and disassembly of beta-amyloid(40) fibrils by short beta-amyloid congeners containing N-methyl amino acids at alternate residues, Biochemistry 40, 8237-8245.
19. Gordon, D. J., and Meredith, S. C. (2003) Probing the role of backbone hydrogen bonding in beta-amyloid fibrils with inhibitor peptides containing ester bonds at alternate positions, Biochemistry 42, 475-485.
20. Findeis, M. A. (2000) Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerization, Biochim. Biophys. Acta 1502, 76-84.
21. Findeis, M. A. (2002) Peptide inhibitors of beta amyloid aggregation, Curr. Top. Med. Chem. 2, 417-423.
22. Xia, W. (2003) Amyloid inhibitors and Alzheimer's disease, Curr. Opin. Invest. Drugs (Thomson Sci.) 4, 55-59.
23. Podlisny, M. B., Walsh, D. M., Amarante, P., Ostaszewski, B. L., Stimson, E. R., Maggio, J. E., Teplow, D. B., and Selkoe, D. J. (1998) Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red, Biochemistry 37, 3602-3611.
24. Bohrmann, B., Adrian, M., Dubochet, J., Kurner, P., Muller, F., Huber, W., Nordstedt, C., and Dobeli, H. (2000) Self-assembly of β-amyloid 42 is retarded by small molecular ligands at the stage of structural intermediates, J. Struct. Biol. 130, 232-246.
25. Chyan, Y.-J., Poeggeller, B., Omar, R. A., Chain, D. G., Frangione, B., Chiso, J., and Pappolla, M. A. (1999) Potent neuroprotective properties against the Alzheimer β-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid, J. Biol. Chem. 274, 21937-21942.
26. Bendheim, P. E., Poeggeler, B., Neria, E., Ziv, V., Pappola, M. A., and Chain, D. G. (2002) Development of indole-3-propionic acid (OXIGON) for Alzheimer's disease, J. Mol. Neurosci. 19, 213-217 and references therein.
27. Reixach, N., Crooks, E., Ostresh, J. M., Houghten, R. A., and Blondelle, S. E. (2000) Inhibition of β-Amyloid-Induced Neurotoxicity by Imidazopyridoindoles Derived from a Synthetic Combinatorial Library, J. Struct. Biol. 130, 247-258.
28. Pepys, M. B., Herbert, J., Hutchinson, W. L., Tennent, G. A., Lachmann, H. J., Gallimore, J. R., Lovat, L. B., Bartfai, T., Alanine, A., Herthel, C., Hoffmann, T., Jakob-Roetne, R., Norcross, R. D., Kemp, J. A., Yamamura, K., Suzuki, M., Taylor, G. W., Murray, S., Thompson, D., Purvis, A., Kolstoe, S., Wood, S. P., and Hawkins, P. N. (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis, Nature 417, 254-259.
29. Adessi, C., Frossard, M.-J., Boissard, C., Fraga, S., Bieler, S., Ruckle, T., Vilbois, F., Robinson, S. M., Mutter, M., Banks, W. A., and Soto, C. (2003) Pharmacological Profiles of Peptide Drug Candidates for the Treatment of Alzheimer's Disease, J. Biol. Chem. 278, 13905-13911.
30. Moore, S. A., Huckerby, T. N., Gibson, G. L., Fullwood, N. J., Turnbull, S. T., Tabner, B. J., El-Agnaf, O. M. A., and Allsop, D. (2004) Both the D-(+) and L-(-) Enantiomers of Nicotine Inhibit Aβ Aggregation and Cytotoxicity, Biochemistry 43, 819-826.
31. Rzepecki, P., Nagel-Steger, L., Feuerstein, S., Linne, U., Molt, O., Zadmard, R., Aschermann, K., Wehner, M., Schader, T., and Riesner, D. (2004) Prevention of Alzheimer's Disease-associated Aβ Aggregation by Rationally Designed Nonpeptidic β-Sheet Ligands, J. Biol. Chem. 279, 47497-47505.
32. Schmuck, C., Frey, P., and Heil, M. (2005) Inhibition of fibril formation of Abeta by guanidiniocarbonyl pyrrole receptors, ChemBioChem 6, 628-631.
33. Ono, K., Hasegawa, K., Naiki, H., and Yamada, M. (2004) Curcumin has potent anti-amyloidogenic effects for Alzheimer's β-amyloid fibrils in vitro, J. Neurosci. Res. 75, 742-750.
34. Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P., Kayed, R., Glabe, C. G., Frautschy, S. A., and Cole, G. M. (2005) Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo, J. Biol. Chem. 280, 5892-5901.
35. Ono, K., Hirohata, M., and Yamada, M. (2005) Ferulic acid destabilizes preformed β-amyloid fibrils in vitro, Biochem. Biophys. Res. Commun. 336, 444-449.
36. Ojima, I., McCarthy, J. R., Welch, J. T., Eds. (1996) Biomedical Frontiers of Fluorine Chemistry, American Chemical Society, Washington, DC.
37. Soloshonok, V. A., Ed. (1999) Enantiocontrolled Synthesis of Fluoroorganic Compunds: Stereochemical Challenges and Biomedicinal Targets, Wiley, New York.
38. Kirsch, P. (2004) Modern Fluoroorganic Chemistry: Synthesis, Reactivity, Applications, Wiley-VCH, New York, Heidelberg.
39. Giacomelli, C. E., and Norde, W. (2003) Influence of Hydrophobic Teflon Particles on the Structure of Amyloid β-Peptide, Biomacromolecules 4, 1719-1726.
40. Vieira, E. P., Hermel, H., and Möhwald, H. (2003) Change and stabilization of the amyloid-β(1-40) secondary structure by fluorocompounds, Biochim. Biophys. Acta 1645, 6-14.
41. Adamski-Werner, S. L., Palaninathan, S. K., Sacchettini, J. C., and Kelly, J. W. (2004) Diflunisal Analogues Stabilize the Native State of Transthyretin. Potent Inhibition of Amyloidogenesis, J. Med. Chem. 47, 355-374.
42. Zhuang, W., Gathergood, N., Hazell, R. G., and Jørgensen, K. A. (2001) Catalytic, Highly Enantio-selective Friedel-Crafts Reactions of Aromatic and Heteroaromatic Compounds to Trifluoropyruvate. A Simple Approach for the Formation of Optically Active Aromatic and Heteroaromatic Hydroxy Trifluoromethyl Esters, J. Org. Chem. 66, 1009-1013.
43. Prakash, G. K. S., Yan, P., Török, B., and Olah, G. A. (2003) Superacid-catalyzed hydroxyalkylation of aromatics with ethyl trifluoropyruvate: a new synthetic route to Mosher's acid analogs, Synlett 527-531.
44. 19F NMR spectroscopy, Tetrahedron: Asymmetry 16, 1547-1555.
45. Török, B., Abid, M., London, G., Esquibel, J., Török, M., Mhadgut, S. C., Yan, P., and Prakash, G. K. S. (2005) Highly enantioselective organocatalytic hydroxyalkylation of indoles with ethyl trifluoropyruvate, Angew. Chem., Int. Ed. 44, 3086-3089.
46. Abid, M., and Török, B. (2005) Synthesis of N-Heteroaryl-(trifluoromethyl)hydroxyalkanoic acid esters by highly efficient solid acid-catalyzed hydroxyalkylation of indoles and pyrroles with activated trifluoromethyl ketones, Adv. Synth. Catal. 347, 1797-1803.
47. Naiki, H., Higuchi, K., Hosokawa, M., and Takeda, T. (1989) Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavine T, Anal. Biochem. 177, 244-249.
48. Levine, H., III (1993) Thioflavin T interaction with synthetic Alzheimer's disease β-amyloid peptides: Detection of amyloid aggregation in solution, Protein Sci. 2, 404-410.
49. Nilsson, M. R. (2004) Techniques to study amyloid fibril formation in vitro, Methods 34, 151-160.
50. Iversen, L. (2002) Amyloid diseases: Small drugs lead the attack, Nature 417, 231-233.
51. Berg, T. (2003) Modulation of protein-protein interactions with small organic molecules, Angew. Chem., Int. Ed. 42, 2462-2481.
52. Török, B., and Prakash, G. K. S. (2003) Synthesis of Chiral Trifluoromethylated Amines by Palladium-Catalyzed Diastereoselective Hydrogenation-Hydrogenolysis Approach, Adv. Synth. Catal. 345, 165-169.
53. Lashuel, H. A., Hartley, D. M., Balakhaneh, D., Aggrawal, A., Teichberg, S., and Callaway, D. J. E. (2002) New Class of Inhibitors of Amyloid-β Fibril Formation. Implications for the mechanism of pathogenesis in Alzheimer's disease, J. Biol. Chem. 277, 42881-42890.